Rebamipide_product_DataBase

Bioactivity

Rebamipide (OPC12759) is an orally active gastroprotective agent that enhances the production of endogenous PGs (especially intragastric PGE2) by inducing COX-2 expression, thereby protecting the gastric mucosa from injury. Rebamipide exerts anti-proliferative activity against gastric cancer cells. Rebamipide can be used in studies of mucosal protection, gastroduodenal ulcer, gastritis and gastric cancer[1][2].

Invitro

Rebamipide (1.4, 2.7, 5.4 mM; 24 h) inhibits proliferation of gastric cancer cell[1].Rebamipide (5.4 mM; 30 min) activates Smad signaling pathway in AGS cells[1].Rebamipide (5.4 mM; 3 h) induces the expression of Cdk inhibitor p21 in AGS cells[1]. Cell Proliferation Assay[1] Cell Line:

In Vivo

Rebamipide (5, 15, 50 mg/kg; p.o.; once daily for 14 days) enhances the expression of COX-2 and PGE2, and protects gastric mucosa from acid-induced injury in rat gastric mucosa[2]. Animal Model:

Name

Rebamipide

CAS

90098-04-7

Formula

C19H15ClN2O4

Molar Mass

370.79

Appearance

Solid

Transport

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Reference

[1]. Tanigawa T, et al. Rebamipide inhibits gastric cancer cell growth. Dig Dis Sci. 2007 Jan;52(1):240-7. [2]. Sun WH, et al. Induction of cyclooxygenase-2 in rat gastric mucosa by rebamipide, a mucoprotective agent. J Pharmacol Exp Ther. 2000 Nov;295(2):447-52.

PeptideDB

Rebamipide

CAS: 90098-04-7 F: C19H15ClN2O4 W: 370.79